送交者: 柯南 于 2005-10-30, 11:48:55:
回答: probably big ones. developing vaccine is not a fancy technique 由 xj 于 2005-10-30, 10:46:17:
http://www.sciam.com/article.cfm?chanID=sa006&colID=1&articleID=000DCB5A-9CC7-134E-9CC783414B7F0000
Caching large amounts of prepandemic
vaccine, though not impossible, is
clearly a challenge. Vaccines expire after
a few years. At current production rates,
a stockpile would never grow to the 228
million doses needed to cover the three
highest priority groups, let alone to the
roughly 600 million doses that would be
needed to vaccinate everyone in the U.S.
Other nations face similar limitations.
The primary reason that capacity is
so tight, Matthews explains, is that vaccine
makers aim only to meet the demand
for annual immunizations when
making business decisions. “We really
don’t see the pandemic itself as a market
opportunity,” he says.
To raise manufacturers’ interest, “we
need to offer a number of incentives,
ranging from liability insurance to better
profi t margins to guaranteed purchases,”
Fauci acknowledges. Long-term
solutions, Gellin predicts, may come
from new technologies that allow vaccines
to be made more effi ciently, to be
scaled up more rapidly, to be effective at
much lower doses and perhaps to work
equally well on all strains of infl uenza.